@salariuspharma.com
Salarius Pharmaceuticals is an oncology based biotechnology company.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Salarius Pharmaceuticals is a cancer-focused biopharmaceutical company that is dedicated to helping patients in need of new treatment options. They utilize targeted protein inhibition and targeted protein degradation to develop innovative therapies that address gene dysregulation in both liquid and solid tumors. Their lead protein inhibitor, seclidemstat (SP-2577), has the potential to bring about a paradigm shift in cancer treatment.
Salarius is focused on targeting Ewing sarcoma, a bone cancer that affects pediatric, adolescent, and young adult patients, where no targeted therapies currently exist. Collaborating with the prestigious MD Anderson Cancer Center, Salarius is also working towards targeting hematologic or blood cancers. Their lead targeted protein degrader, SP-3164, is a unique molecular glue that selectively degrades transcription factors Ikaros and Aiolos, with the potential to treat hematological cancers and solid tumors.
This groundbreaking therapy is expected to enter clinical trials in the second half of 2023, offering hope to patients in need
Company Type
Public Company
Company Size
11-50
Year Founded
2011
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories